

**Drug-drug interactions between glucagon-like peptide 1 receptor agonists and oral medications: a systematic review**

**Journal: Drug Safety**

Authors: Bronya Calvarysky, Idit Dotan, Daniel Shepshelovich, Avi Leader, and Talia Diker Cohen

Corresponding author:

Talia Diker-Cohen, MD PhD

Institute of Endocrinology, Diabetes & Metabolism, Rabin Medical Center, Beilinson Hospital,

39 Jabotinski St., Petach Tikva, Israel 4941492.

Tel: +972-3-9377182; Fax: +972-3-9377181 | E-mail: [proftdc@gmail.com](mailto:proftdc@gmail.com)

Supplementary Table 1. Quality of reporting

	Design	Sample size	Exposure	Outcome	Timing	Intersubjective Variability	Population	Steady state of perpetrator drug	Assay/ analyses and validation
Kothare PA 2005(1)	Good	Good	Good	Good	Good	Good	Fair	Good	Good
Blase E 2005(2)	Good	Good	Good	Good	Fair	Good	Good	Fair	Good
Soon D 2006(3)	Good	Good	Good	Good	Good	Good	Fair	Good	Good
Kothare PA 2007(4)	Good	Good	Good	Good	Good	Good	Good	Good	Good
Linnebjerg H 2009(5)	Good	Good	Good	Good	Good	Good	Good	Good	Good
Kothare PA 2012(6)	Good	Good	Good	Good	Good	Good	Good	Good	Good
Kapitza C 2011(7)	Good	Good	Good	Good	Fair	Good	Good	Good	Good
Jacobsen LV 2011(8)	Good	Good	Good	Good	Fair	Good	Good	Good	Good
Malm-Erjefält M 2015(9)	Good	Good	Good	Good	Atorvastatin, lisinopril – Good; Digoxin - Fair	Good	Good	Good	Good
Pinelli NR 2013(10)	Good	Poor	Good	Good	Good	Good	Fair	Good	Good

Bush M 2012(11)	(12)Good	Good	Good	Good	Digoxin – Fair; Warfarin, COC - good	Good	Digoxin – Fair; Warfarin, COC - good	Good	Good
de la Peña A 2017(12)	Digoxin, atorvastatin: Fair Warfarin, COC: Good	Good	Good	Good	Digoxin, atorvastatin, COC – Good; Warfarin - fair	Good	Good	Digoxin study – Good; Warfarin, atorvastatin, COC studies-poor	Good
Kapitza C 2015(13)	Good	Good	Good	Good	Good	Good	Good	Good	Good
Hausner H 2017(14)	Good	Good	Good	Good	Warfarin, atorvastatin– Good; Digoxin - Fair	Good	Good	Good	Good
Langeskov EK 2022(15)	Good	Good	Good	Good	Good	Good	Good	Good	Good
Meier JJ 2005(16)	Good	Fair	Good	Good	Good	Good	Fair	Good	Good

COC – combined oral contraceptives.

## References

1. Kothare PA, Soon DK, Linnebjerg H, Park S, Chan C, Yeo A, et al. Effect of exenatide on the steady-state pharmacokinetics of digoxin. *J Clin Pharmacol.* 2005;45(9):1032-7.
2. Blase E, Taylor K, Gao HY, Wintle M, Fineman M. Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. *J Clin Pharmacol.* 2005;45(5):570-7.
3. Soon D, Kothare PA, Linnebjerg H, Park S, Yuen E, Mace KF, et al. Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men. *J Clin Pharmacol.* 2006;46(10):1179-87.
4. Kothare PA, Linnebjerg H, Skrivaneck Z, Reddy S, Mace K, Pena A, et al. Exenatide effects on statin pharmacokinetics and lipid response. *Int J Clin Pharmacol Ther.* 2007;45(2):114-20.
5. Linnebjerg H, Kothare P, Park S, Mace K, Mitchell M. The effect of exenatide on lisinopril pharmacodynamics and pharmacokinetics in patients with hypertension. *Int J Clin Pharmacol Ther.* 2009;47(11):651-8.
6. Kothare PA, Seger ME, Northrup J, Mace K, Mitchell MI, Linnebjerg H. Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial. *BMC Clin Pharmacol.* 2012;12:8.
7. Kapitza C, Zdravkovic M, Hindsberger C, Flint A. The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen. *Adv Ther.* 2011;28(8):650-60.
8. Jacobsen LV, Vouis J, Hindsberger C, Zdravkovic M. Treatment with liraglutide-a once-daily GLP-1 analog-does not reduce the bioavailability of ethinyl estradiol/levonorgestrel taken as an oral combination contraceptive drug. *Journal of Clinical Pharmacology.* 2011;51(12):1696-703.
9. Malm-Erjefält M, Ekblom M, Vouis J, Zdravkovic M, Lennernäs H. Effect on the Gastrointestinal Absorption of Drugs from Different Classes in the Biopharmaceutics Classification System, When Treating with Liraglutide. *Mol Pharm.* 2015;12(11):4166-73.
10. Pinelli NR, Patel A, Salinitri FD. Coadministration of liraglutide with tacrolimus in kidney transplant recipients: A case series. *Diabetes Care.* 2013;36(10):e171-e2.
11. Bush M, Scott R, Watanalumlerd P, Zhi H, Lewis E. Effects of multiple doses of albiglutide on the pharmacokinetics, pharmacodynamics, and safety of digoxin, warfarin, or a low-dose oral contraceptive. *Postgrad Med.* 2012;124(6):55-72.
12. de la Peña A, Cui X, Geiser J, Loghin C. No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide. *Clin Pharmacokinet.* 2017;56(11):1415-27.
13. Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. *J Clin Pharmacol.* 2015;55(5):497-504.
14. Hausner H, Derving Karsbøl J, Holst AG, Jacobsen JB, Wagner FD, Golor G, et al. Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects. *Clin Pharmacokinet.* 2017;56(11):1391-401.
15. Langeskov EK, Kristensen K. Population pharmacokinetic of paracetamol and atorvastatin with co-administration of semaglutide. *Pharmacol Res Perspect.* 2022;10(4):e00962.

16. Meier JJ, Kemmeries G, Holst JJ, Nauck MA. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. *Diabetes*. 2005;54(7):2212-8.